EGFR and non-small cell lung carcinoma: Public database analysis revealed that the EGFR/TP53/CUL3 triple mutation accounts for 0.4% of EGFR‐mutant NSCLC cases, yielding significantly shorter survival than EGFR mutations alone and likely shorter than EGFR/TP53 double mutations.